- Home
- Industry Reports
- Healthcare
- Middle East & Africa Biosimilar Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Biosimilar or follow-on-biologics are similar to the brand biopharmaceutical drugs which are synthetic versions of original products. Biosimilars have a patent expiration, and their developments are the crucial part of the overall growth of biosimilar market. Biosimilars are derived from yeast, animals, bacteria, plants, and viruses.
The Middle East & Africa Biosimilars Market Segments Size & Growth:
The Middle East & Africa Biosimilars Market is accounted for $ XX billion in 2017 and expected to grow at a CAGR of XX% to reach $XX billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth are next-gen business, high growth in chronic diseases, and less cost biosimilar drugs. However, high initial investments in research hinder the growth of the protein expression market.
The Middle East & Africa Biosimilars Market Segments Share:
The Middle East & Africa Biosimilars Market is categorised into by-product which consists of insulin, interferon, human growth hormone, and granulocyte colony-stimulating factor. Granulocyte colony-stimulating factor has the most significant share as they are cheaper compared to others. By services, the Middle East & Africa biosimilars market is segmented into clinical trials and contract research and manufacturing services. Among all clinical trials are expected to have high growth rate during the forecast period 2018-2024, due to increase in demand for low-cost drugs and vaccines that can treat various chronic diseases. The technology is segregated into chromatography, recombinant DNA technology, monoclonal antibodies technology, and nuclear magnetic resonance technology. Monoclonal antibodies technology is expected to have the most significant share in the market due to treating chronic diseases in a single operation
Blood disorders and autoimmune disease are leading in biosimilars among applications owing to the change in patent scenario and high-rated biologics. By Geography, South Africa is dominating the biosimilars market, and the growth in Middle East & Africa is mainly attributed because of the favourable government’s regulations. Furthermore, Middle East is witnessing the fastest growth during the forecast period, due to rising chronic diseases, adoption of biosimilar drugs and investment in R&D research.
The Middle East & Africa Biosimilars Market Segments Trends:
- In January 2018, Novartis and Biocon have developed their biosimilar drug for the next generation in immunology and oncology.
- Emerging technology in biosimilars market is stem cell technology in the Middle East & Africa region.
- In a recent study, biosimilar drugs will cut down the cost of biologics which helps in treating diseases like cancer and other chronic disorders intern replace the biologics in the market.
The Middle East & Africa Biosimilars Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Zydus Cadila Healthcare
- Biocon
- Bioxpress Therapeutics
- Apotex
- Accord Healthcare
- Hexal
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Models on Next-Gen Business
4.1.2 High growth in the prevalence of chronic diseases
4.1.3 Less cost biosimilar drugs
4.2 Restraints
4.2.1 High initial investment in research
4.2.2 Complexity in production
4.3 Opportunities
4.3.1 Emerging from biosimilar drugs
4.4 Challenges
4.4.1. Low cost compared to original products
Chapter 5 Middle East & Africa Biosimilar Market – By Product
5.1 Insulin
5.2 Interferon
5.3 Human Growth Hormone
5.4 Granulocyte colony-stimulating factor
5.5 Others
Chapter 6 Middle East & Africa Biosimilar Market – By Services
6.1 Clinical trials
6.2 Contract research & manufacturing services
Chapter 7 Middle East & Africa Biosimilar Market – By Technology
7.1. Chromatography
7.2 Recombinant DNA Technology
7.3 Monoclonal Antibodies Technology
7.4 Nuclear magnetic resonance Technology
7.5 Others
Chapter 8 Middle East & Africa Biosimilar Market – By Application
8.1 Oncology diseases
8.2 Chronic and autoimmune diseases
8.3 Blood disorders
8.4 Growth hormone deficiency
8.5 Others
Chapter 9 Middle East & Africa Biosimilar Market – By Geography
9.1 Introduction
9.2 The Middle East & Africa
9.2.1. The Middle East
9.2.2. Africa
Chapter 10 Middle East & Africa Biosimilar Market – Company Profiles
10.1. Zydus Cadila Healthcare
10.2. Biocon
10.3. Bioxpress Therapeutics
10.4. Apotex
10.5. Accord Healthcare
10.6. Hexal
10.7. LG Life Sciences Limited
10.8. Novartis/Sandoz
10.9. Teva Pharmaceuticals
10.10. Hospira
10.11. Samsung Bioepis
10.12. Eli Lilly
10.13. Harvest Moon Pharmaceuticals
10.14. Mylan
10.15. Celltrion
Chapter 11 Middle East & Africa Biosimilar Market – Competitive Landscape
11.1. Market Share Analysis
11.2. Strategies Adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 12 Market Insights
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €2,030.46 - €6,768.19
- INR: ₹180,726.90 - ₹602,423.01
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,734.01 - £5,780.03
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Biosimilar or follow-on-biologics are similar to the brand biopharmaceutical drugs which are synthetic versions of original products. Biosimilars have a patent expiration, and their developments are the crucial part of the overall growth of biosimilar market. Biosimilars are derived from yeast, animals, bacteria, plants, and viruses.
The Middle East & Africa Biosimilars Market Segments Size & Growth:
The Middle East & Africa Biosimilars Market is accounted for $ XX billion in 2017 and expected to grow at a CAGR of XX% to reach $XX billion by 2024 during the forecast period 2018-2024. Major factors that are driving the market growth are next-gen business, high growth in chronic diseases, and less cost biosimilar drugs. However, high initial investments in research hinder the growth of the protein expression market.
The Middle East & Africa Biosimilars Market Segments Share:
The Middle East & Africa Biosimilars Market is categorised into by-product which consists of insulin, interferon, human growth hormone, and granulocyte colony-stimulating factor. Granulocyte colony-stimulating factor has the most significant share as they are cheaper compared to others. By services, the Middle East & Africa biosimilars market is segmented into clinical trials and contract research and manufacturing services. Among all clinical trials are expected to have high growth rate during the forecast period 2018-2024, due to increase in demand for low-cost drugs and vaccines that can treat various chronic diseases. The technology is segregated into chromatography, recombinant DNA technology, monoclonal antibodies technology, and nuclear magnetic resonance technology. Monoclonal antibodies technology is expected to have the most significant share in the market due to treating chronic diseases in a single operation
Blood disorders and autoimmune disease are leading in biosimilars among applications owing to the change in patent scenario and high-rated biologics. By Geography, South Africa is dominating the biosimilars market, and the growth in Middle East & Africa is mainly attributed because of the favourable government’s regulations. Furthermore, Middle East is witnessing the fastest growth during the forecast period, due to rising chronic diseases, adoption of biosimilar drugs and investment in R&D research.
The Middle East & Africa Biosimilars Market Segments Trends:
- In January 2018, Novartis and Biocon have developed their biosimilar drug for the next generation in immunology and oncology.
- Emerging technology in biosimilars market is stem cell technology in the Middle East & Africa region.
- In a recent study, biosimilar drugs will cut down the cost of biologics which helps in treating diseases like cancer and other chronic disorders intern replace the biologics in the market.
The Middle East & Africa Biosimilars Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Zydus Cadila Healthcare
- Biocon
- Bioxpress Therapeutics
- Apotex
- Accord Healthcare
- Hexal
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter’s Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Models on Next-Gen Business
4.1.2 High growth in the prevalence of chronic diseases
4.1.3 Less cost biosimilar drugs
4.2 Restraints
4.2.1 High initial investment in research
4.2.2 Complexity in production
4.3 Opportunities
4.3.1 Emerging from biosimilar drugs
4.4 Challenges
4.4.1. Low cost compared to original products
Chapter 5 Middle East & Africa Biosimilar Market – By Product
5.1 Insulin
5.2 Interferon
5.3 Human Growth Hormone
5.4 Granulocyte colony-stimulating factor
5.5 Others
Chapter 6 Middle East & Africa Biosimilar Market – By Services
6.1 Clinical trials
6.2 Contract research & manufacturing services
Chapter 7 Middle East & Africa Biosimilar Market – By Technology
7.1. Chromatography
7.2 Recombinant DNA Technology
7.3 Monoclonal Antibodies Technology
7.4 Nuclear magnetic resonance Technology
7.5 Others
Chapter 8 Middle East & Africa Biosimilar Market – By Application
8.1 Oncology diseases
8.2 Chronic and autoimmune diseases
8.3 Blood disorders
8.4 Growth hormone deficiency
8.5 Others
Chapter 9 Middle East & Africa Biosimilar Market – By Geography
9.1 Introduction
9.2 The Middle East & Africa
9.2.1. The Middle East
9.2.2. Africa
Chapter 10 Middle East & Africa Biosimilar Market – Company Profiles
10.1. Zydus Cadila Healthcare
10.2. Biocon
10.3. Bioxpress Therapeutics
10.4. Apotex
10.5. Accord Healthcare
10.6. Hexal
10.7. LG Life Sciences Limited
10.8. Novartis/Sandoz
10.9. Teva Pharmaceuticals
10.10. Hospira
10.11. Samsung Bioepis
10.12. Eli Lilly
10.13. Harvest Moon Pharmaceuticals
10.14. Mylan
10.15. Celltrion
Chapter 11 Middle East & Africa Biosimilar Market – Competitive Landscape
11.1. Market Share Analysis
11.2. Strategies Adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 12 Market Insights
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.